Monoclonal Antibody to Brain Natriuretic Peptide (BNP)
Code | Size | Price |
---|
MAA541Hu25-20ul | 20ul | £80.00 |
Quantity:
MAA541Hu25-100ul | 100ul | £147.00 |
Quantity:
MAA541Hu25-200ul | 200ul | £196.00 |
Quantity:
MAA541Hu25-1ml | 1ml | £445.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
GC-B; B-Type Natriuretic Peptide; Ventricular Natriuretic Peptide; Gamma-brain natriuretic peptide; Brain natriuretic peptide 32
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Ig Isotype:
IgG2b Kappa
Immunogen:
RPA541Hu01-Recombinant Brain Natriuretic Peptide (BNP)
Item Name:
Brain Natriuretic Peptide
Potency (Clone Number):
C12
Source:
Monoclonal antibody preparation
Subcategory:
Monoclonal antibody preparation
USAGE:
Western blotting: 0.5-3ug/mL;<br/>
Immunohistochemistry: 5-30ug/mL;<br/>
Immunocytochemistry: 5-30ug/mL;<br/>
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-30ug/mL;<br/>
Immunocytochemistry: 5-30ug/mL;<br/>
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OVA Conjugated Brain Natriuretic Peptide (BNP) | CPA541Hu21 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||